NGM NGM Biopharmaceuticals

NGM Bio to Participate in Upcoming Investor Conferences

NGM Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update. Management will also be available for investor meetings at the upcoming Jefferies London Healthcare Conference.

Jefferies London Healthcare Conference 2023

November 14 – 16, 2023

6th Annual Evercore ISI HealthCONx Conference

Wednesday, November 29, 2023, 8:45 am ET

About NGM Bio

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Visit us at for more information.

Investor Contact:

Media Contact:

 

 

 



EN
07/11/2023

Underlying

NGMNGM Biopharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NGM Biopharmaceuticals

 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio Announces Closing of Tender Offer

NGM Bio Announces Closing of Tender Offer SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain oth...

April 5, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ong...

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have be...

March 19, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter...

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravida...

March 11, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger wit...

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transactionBased on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transaction SAN FRANCISCO, Feb. 26, 2...

February 26, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET. A live webcast of the presentation will be available under the Investors and M...

February 20, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch